Renal fibrosis: not just PAI-1 in the sky.

Abstract excerpt

A delicate balance exists between ECM synthesis and degradation such that interruption of the corresponding pathways results in increased plasminogen activator inhibitor-1 (PAI-1), pathological matrix accumulation, and glomerulosclerosis. A new study demonstrates that therapy with a mutant PAI-1 increases matrix turnover and reduces glomerulosclerosis by competing with endogenous PAI-1, suggesting therapeutic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Macrophages
• Share to Mice, Knockout
• Share to Cell Movement